Shirley R. Kuhlmann Sells 40,000 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company’s stock, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Collegium Pharmaceutical Trading Down 3.0 %

NASDAQ:COLL opened at $28.91 on Friday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The business’s 50 day moving average is $30.78 and its two-hundred day moving average is $33.23. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company has a market cap of $910.26 million, a PE ratio of 12.46 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on COLL. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Friday, January 10th. Piper Sandler reduced their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Institutional Trading of Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in COLL. Farther Finance Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 5,408.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 11,678 shares of the specialty pharmaceutical company’s stock worth $451,000 after purchasing an additional 11,466 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Collegium Pharmaceutical by 4.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock worth $908,000 after purchasing an additional 983 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Collegium Pharmaceutical by 265.9% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 114,965 shares of the specialty pharmaceutical company’s stock worth $4,442,000 after purchasing an additional 83,548 shares during the last quarter. Principal Financial Group Inc. raised its stake in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after acquiring an additional 64,958 shares in the last quarter. Finally, Easterly Investment Partners LLC raised its stake in Collegium Pharmaceutical by 31.7% during the 3rd quarter. Easterly Investment Partners LLC now owns 56,158 shares of the specialty pharmaceutical company’s stock valued at $2,170,000 after acquiring an additional 13,529 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.